The $0.108 initial offer price represents a significant premium over a micro-cap OTC stock, but the deal faces multiple conditions including CFIUS review, the Alchemy acquisition, and a 90% minimum tender threshold. Monitor the Schedule TO filing and CFIUS declaration for progress; the long-stop date of March 31, 2027 provides a timeline for potential failure. The concurrent Alchemy acquisition adds execution risk.
Price Chart
Executive Summary
Cavitation Technologies, Inc. (CVAT) entered into a definitive tender offer agreement with European Guarantee Services S.à.r.l. (EGS), a Luxembourg-based financial firm, for EGS to acquire all outstanding CVAT shares for $35 million in cash, less indebtedness and liabilities. The initial offer price is $0.108 per share based on 317,220,739 shares outstanding and $645,650.41 in combined indebtedness and liabilities, though the final price will adjust based on a later record date. The deal is contingent on several conditions, including EGS's concurrent acquisition of Alchemy Beverages Inc. for $7 million, at least 90% of CVAT shares being tendered, and CFIUS approval, with a long-stop date of March 31, 2027.
Key Financial Metrics
Key Facts
- EGS to acquire all CVAT shares for $35 million in cash, less indebtedness and liabilities.
- Initial offer price set at $0.108 per share based on 317,220,739 shares outstanding and $645,650.41 in combined indebtedness and liabilities.
- Concurrent acquisition of Alchemy Beverages Inc. for $7 million is a condition to the CVAT tender offer.
- Offer requires at least 90% of CVAT shares to be tendered.
- Transaction subject to CFIUS review and other customary conditions; long-stop date is March 31, 2027.
- CVAT board unanimously recommends shareholders accept the offer.
- No shareholder vote required for the tender offer.
Financial Impact
Total cash consideration of $35 million for CVAT shares, with an initial per-share price of $0.108. Combined with the Alchemy acquisition, aggregate cash consideration is $42 million.
Risk Factors
- CFIUS review could block or delay the transaction given the foreign acquirer.
- Failure to achieve the 90% minimum tender condition could scuttle the deal.
- The Alchemy acquisition is a condition precedent and may not close.
- Financing is reliant on Bright Wealth Banking Consultant, a Dubai-based affiliate of the purchaser, adding counterparty risk.
- The final offer price may be reduced by adjustments for indebtedness and liabilities, and diluted by warrant/convertible exercises and a planned private placement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-006581 |
| Document: cavitation_8k.htm | 0001683168-26-006581 |
| Document: cavitation_ex9901.htm | 0001683168-26-006581 |
| Document: 0001683168-26-006581-index-headers.html | 0001683168-26-006581 |
| Document: 0001683168-26-006581-index.html | 0001683168-26-006581 |
| Document: 0001683168-26-006581.txt | 0001683168-26-006581 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | SC TO-T | $0.0400 | awaiting T+5 | — | $0.0318 (−20.50%) |
Oct 13, 2026 14d ago | 8-K | $0.0300 $0.0300 | · 0.00% | ▲ +1.15% | $0.0318 (+6.00%) |
Sep 28, 2026 28d ago | NT 10-K | $0.0400 $0.0400 | · 0.00% | ▲ +1.20% | $0.0318 (+20.50%) |
Aug 19, 2026 9w ago | 8-K | $0.0400 $0.0443 | ▲ +10.75% | ▲ +11.14% | $0.0318 (−20.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers